Cancer treatment according to BRCA1 and BRCA2 mutations

Nature Reviews Clinical Oncology

Volumn 9, Issue 9, 2012, Pages 520-528

  Maxwell, Kara N ^a   Domchek, Susan M ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CA 125 ANTIGEN; CARBOPLATIN; CISPLATIN; CRIZOTINIB; DACARBAZINE; DASATINIB; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; INIPARIB; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NILOTINIB; OLAPARIB; VANDETANIB; VELIPARIB; VEMURAFENIB;

ANEMIA; BREAST CANCER; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CANCER THERAPY; CLINICAL PRACTICE; DIAGNOSTIC TEST; DRUG DOSAGE FORM COMPARISON; FATIGUE; GENE MUTATION; GENE TARGETING; GERM LINE GENE THERAPY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; NAUSEA; OVARY CANCER; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; THYROID MEDULLARY CARCINOMA; TRANSVAGINAL ECHOGRAPHY; TUMOR SUPPRESSOR GENE;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; HUMANS; MUTATION; RISK; UTERINE NEOPLASMS; WOMEN'S HEALTH;

EID: 84865688579     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2012.123     Document Type: Review

References (103)

1. Davies, C. et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet 378, 771-784 (2011).
2. Burstein, H. J. et al. American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J. Clin. Oncol. 28, 3784-3796 (2010).
3. Murphy, C. G. & Fornier, M. HER2-positive breast cancer: beyond trastuzumab. Oncology (Williston Park) 24, 410-415 (2010).
4. Gudmundsdottir, K. & Ashworth, A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 25, 5864-5874 (2006).
5. O'Donovan, P. J. & Livingston, D. M. BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair. Carcinogenesis 31, 961-967 (2010).
6. Antoniou, A. et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am. J. Hum. Genet. 72, 1117-1130 (2003).
7. [No authors listed] Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium. J. Natl Cancer Inst. 91, 1310-1316 (1999).
8. Neuhausen, S. L. et al. BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research. Breast Cancer Res. Treat. 116, 379-386 (2009).
9. Daly, M. B. et al. Genetic/familial high-risk assessment: breast and ovarian. J. Natl Compr. Canc. Netw. 8, 562-594 (2010).
10. Cook-Deegan, R. et al. Impact of gene patents and licensing practices on access to genetic testing for inherited susceptibility to cancer: comparing breast and ovarian cancers with colon cancers. Genet. Med. 12(Suppl. 4), 15-38 (2010).
11. Kriege, M. et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N. Engl. J. Med. 351, 427-437 (2004).
12. Kuhl, C. et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J. Clin. Oncol. 28, 1450-1457 (2010).
13. Saslow, D. et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J. Clin. 57, 75-89 (2007).
14. Balmana, J., Diez, O., Rubio, I. T. & Cardoso, F. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann. Oncol. 22(Suppl. 6), 31-34 (2011).
15. Hemel, D. & Domchek, S. M. Breast cancer predisposition syndromes. Hematol. Oncol. Clin. North Am. 24, 799-814 (2010).
16. Gronwald, J. et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int. J. Cancer 118, 2281-2284 (2006).
17. King, M. C. et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP. P1) Breast Cancer Prevention Trial. JAMA 286, 2251-2256 (2001).
18. Domchek, S. M. et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 304, 967-975 (2010).
19. Osorio, A. et al. Loss of heterozygosity analysis at the BRCA loci in tumor samples from patients with familial breast cancer. Int. J. Cancer 99, 305-309 (2002).
20. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005).
21. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP.ribose) polymerase. Nature 434, 913-917 (2005).
22. Venkitaraman, A. R. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 108, 171-182 (2002).
23. Strom, C. E. et al. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res. 39, 3166-3175 (2011).
24. Javle, M. & Curtin, N. J. The role of PARP in DNA repair and its therapeutic exploitation. Br. J. Cancer 105, 1114-1122 (2011).
25. Helleday, T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol. Oncol. 5, 387-393 (2011).
26. Fong, P. C. et al. Inhibition of poly (ADP-ribose) polymerase in tumors from BRCA mutation carriers. N. Engl. J. Med. 361, 123-134 (2009).
27. Fong, P. C. et al. Poly (ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J. Clin. Oncol. 28, 2512-2519 (2010).
28. Tutt, A. et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof.of.concept trial. Lancet 376, 235-244 (2010).
29. Audeh, M. W. et al. Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof.of.concept trial. Lancet 376, 245-251 (2010).
30. Kaye, S. B. et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J. Clin. Oncol. 30, 372-379 (2012).
31. Gordon, A. N. et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19, 3312-3322 (2001).
32. Adams, S. F. et al. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cancer. Gynecol. Oncol. 123, 486-491 (2011).
33. Yang, D. et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306, 1557-1565 (2011).
34. Fogelman, D. R. et al. Evidence for the efficacy of iniparib, a PARP.1 inhibitor, in BRCA2-associated pancreatic cancer. Anticancer Res. 31, 1417-1420 (2011).
35. Sandhu, S. et al. First.in. human trial of a poly (ADP-ribose) polymerase (PARP) inhibitor MK.4827 in advanced cancer patients (pts) with antitumor activity in BRCA-deficient and sporadic ovarian cancers [abstract]. J. Clin. Oncol. 28(Suppl. 15), a3001 (2010).
36. Kummar, S. et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin. Cancer Res. 18, 1726-1734 (2012).
37. Clinical Trials.gov [online] http://clinicaltrials.gov/ (2012).
38. Hennessy, B. T. et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J. Clin. Oncol. 28, 3570-3576 (2010).
39. Gelmon, K. A. et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. Lancet Oncol. 12, 852-861 (2011).
40. Penson, R. T. et al. A phase II trial of iniparib (BSI.201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-sensitive recurrent ovarian cancer [abstract]. J. Clin. Oncol. 29(Suppl.), a5004 (2011).
41. Birrer, M. J. et al. A phase II trial of iniparib (BSI.201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer [abstract]. J. Clin. Oncol. 29, a5005 (2011).
42. Ledermann, J. et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N. Engl. J. Med. 366, 1382-1392 (2012).
43. Konstantinopoulos, P. A. et al. Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J. Clin. Oncol. 28, 3555-3561 (2010).
44. Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938-1948 (2010).
45. Turner, N., Tutt, A. & Ashworth, A. Hallmarks of 'eBRCAness' in sporadic cancers. Nat. Rev. Cancer 4, 814-819 (2004).
46. Turner, N. C. et al. BRCA1 dysfunction in sporadic basal-like breast cancer. Oncogene 26, 2126-2132 (2007).
47. Hastak, K., Alli, E. & Ford, J. M. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly (ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin. Cancer Res. 70, 7970-7980 (2010).
48. Natrajan, R. et al. An integrative genomic and transcriptomic analysis reveals molecular pathways and networks regulated by copy number aberrations in basal-like, HER2 and luminal cancers. Breast Cancer Res. Treat. 121, 575-589 (2010).
49. O'Shaughnessy, J. et al. Iniparib plus chemotherapy in metastatic triple-negative breast cancer. N. Engl. J. Med. 364, 205-214 (2011).
50. O'Shaughnessy, J. et al. A randomized phase III study of iniparib (BSI.201) in combination with gemcitabine/carboplatin (G/C) in metastatic triple-negative breast cancer (TNBC) [abstract]. J. Clin. Oncol. 29, a1007 (2011).
51. Liu, X. et al. Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor. Clin. Cancer Res. 18, 510-523 (2012).
52. Patel, A. G., De Lorenzo, S. B., Flatten, K. S., Poirier, G. G. & Kaufmann, S. H. Failure of iniparib to inhibit poly (ADP-Ribose) polymerase in vitro. Clin. Cancer Res. 18, 1655-1662 (2012).
53. Carey, L. A. et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin. Cancer Res. 13, 2329-2334 (2007).
54. Metzger-Filho, O. et al. Dissecting the heterogeneity of triple-negative breast cancer. J. Clin. Oncol. 30, 1879-1887 (2012).
55. Tutt, A. & Ashworth, A. Can genetic testing guide treatment in breast cancer? Eur. J. Cancer 44, 2774-2780 (2008).
56. Edwards, S. L. et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451, 1111-1115 (2008).
57. Swisher, E. M. et al. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. Cancer Res. 68, 2581-2586 (2008).
58. Sakai, W. et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 69, 6381-6386 (2009).
59. Norquist, B. et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J. Clin. Oncol. 29, 3008-3015 (2011).
60. Kummar, S. et al. Advances in using PARP inhibitors to treat cancer. BMC Med. 10, 25 (2012).
61. Ernst, T. & Hochhaus, A. Chronic myeloid leukemia: clinical impact of BCR-ABL1 mutations and other lesions associated with disease progression. Semin. Oncol. 39, 58-66 (2011).
62. Domchek, S. M. et al. Challenges to the development of new agents for molecularly defined patient subsets: lessons from BRCA1/2.associated breast cancer. J. Clin. Oncol. 29, 4224-4226 (2011).
63. John, E. M. et al. Prevalence of pathogenic BRCA1 mutation carriers in 5 US racial/ethnic groups. JAMA 298, 2869-2876 (2007).
64. Malone, K. E. et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res. 66, 8297-8308 (2006).
65. Zhang, S. et al. Frequencies of BRCA1 and BRCA2 mutations among 1, 342 unselected patients with invasive ovarian cancer. Gynecol. Oncol. 121, 353-357 (2011).
66. Papelard, H. et al. Prevalence of BRCA1 in a hospital-based population of Dutch breast cancer patients. Br. J. Cancer 83, 719-724 (2000).
67. Risch, H. A. et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am. J. Hum. Genet. 68, 700-710 (2001).
68. Howlader, N. et al. (eds) SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2009-pops09/, based on November 2011 SEER data submission, posted to the SEER web site, April 2012.
69. Arun, B. et al. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience. J. Clin. Oncol. 29, 3739-3746 (2011).
70. Richards, M. L. Familial syndromes associated with thyroid cancer in the era of personalized medicine. Thyroid 20, 707-713 (2010).
71. Wells, S. A. Jr et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Oncol. 28, 767-772 (2010).
72. Martins, R. G., Rajendran, J. G., Capell, P., Byrd, D. R. & Mankoff, D. A. Medullary thyroid cancer: options for systemic therapy of metastatic disease? J. Clin. Oncol. 24, 1653-1655 (2006).
73. Wells, S. A. Jr et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J. Clin. Oncol. 30, 134-141 (2012).
74. Curtin, J. A. et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135-2147 (2005).
75. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
76. Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819 (2010).
77. Sosman, J. A. et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med. 366, 707-714 (2012).
78. Chapman, P. B. et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516 (2011).
79. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non. small.cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
80. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
81. Maemondo, M. et al. Gefitinib or chemotherapy for non. small.cell lung cancer with mutated EGFR. N. Engl. J. Med. 362, 2380-2388 (2010).
82. Mitsudomi, T. et al. Gefitinib versus cisplatin plus docetaxel in patients with non. small.cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol. 11, 121-128 (2010).
83. Rosell, R. et al. Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial [abstract]. J. Clin. Oncol. 29, a7503 (2011).
84. Zhou, C. et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non. small.cell lung cancer (OPTIMAL, CTONG.0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 12, 735-742 (2011).
85. Shepherd, F. A. et al. Erlotinib in previously treated non. small.cell lung cancer. N. Engl. J. Med. 353, 123-132 (2005).
86. Cohen, M. H., Johnson, J. R., Chen, Y. F., Sridhara, R. & Pazdur, R. FDA drug approval summary: erlotinib (Tarceva) tablets. Oncologist 10, 461-466 (2005).
87. Soda, M. et al. Identification of the transforming EML4-ALK fusion gene in non. small.cell lung cancer. Nature 448, 561-566 (2007).
88. Sasaki, T., Rodig, S. J., Chirieac, L. R. & Janne, P. A. The biology and treatment of EML4. ALK non-small cell lung cancer. Eur. J. Cancer 46, 1773-1780 (2010).
89. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non. small.cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2011).
90. Shaw, A. T. et al. Effect of crizotinib on overall survival in patients with advanced non. small.cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 12, 1004-1012 (2011).
91. Wong, D. W. et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115, 1723-1733 (2009).
92. US National Library of Medicine. Clinical Trials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01154140 (2012).
93. Sridhar, S. S., Seymour, L. & Shepherd, F. A. Inhibitors of epidermal.growth.factor receptors: a review of clinical research with a focus on non. small.cell lung cancer. Lancet Oncol. 4, 397-406 (2003).
94. Keedy, V. L. et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non. small.cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J. Clin. Oncol. 29, 2121-2127 (2011).
95. John, T., Liu, G. & Tsao, M. S. Overview of molecular testing in non. small.cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors. Oncogene 28(Suppl. 1), 14-23 (2009).
96. Shaw, A. T., Solomon, B. & Kenudson, M. M. Crizotinib and testing for ALK. J. Natl Compr. Canc. Netw. 9, 1335-1341 (2011).
97. Halait, H. et al. Analytical performance of a real-time PCR-based assay for V600 mutations in the BRAF gene, used as the companion diagnostic test for the novel BRAF inhibitor vemurafenib in metastatic melanoma. Diagn. Mol. Pathol. 21, 1-8 (2012).
98. US Food and Drug Administration. Draft Guidance for Industry and Food and Drug Administration Staff-In Vitro Companion Diagnostic Devices [online]. http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ ucm262292.htm (2011).
99. Southern District of New York, Association for Molecular Pathology v. U. S. Patent and Trademark Office, No. 09 cv 4515, http://www.cafc.uscourts.gov/ images/stories/opinions-orders/2010-1406-8-16-10-1.pdf (2010).
100. Devi, S. BRCA patent dispute may head to US Supreme Court. Lancet 379, 300 (2012).
101. Liptak, A. Justices Back Mayo Clinic Argument on Patents. The New York Times (New York) B3 (21 Mar. 2012).
102. Pollack, A. Justices Send Back Gene Case. The New York Times (New York) B1 (27 Mar. 2012).
103. Perez-Soler, R. et al. Determinants of tumor response and survival with erlotinib in patients with non-.small.cell lung cancer. J. Clin. Oncol. 22, 3238-3247 (2004).